(FLGT) Fulgent Genetics, Inc. Marketing Mix Research |
Fully Editable: Tailor To Your Needs In Excel Or Sheets
Professional Design: Trusted, Industry-Standard Templates
Investor-Approved Valuation Models
MAC/PC Compatible, Fully Unlocked
No Expertise Is Needed; Easy To Follow
(FLGT) Fulgent Genetics, Inc. Complete Analysis Pack
See the Bigger Picture
This Fulgent Genetics, Inc. 4P's Marketing Mix Analysis shows what the company sells, how it prices and distributes offerings, and how it promotes them—useful for marketing strategy, benchmarking, or reports. The content on this page is a real preview/sample of the analysis; purchase the full version to get the complete ready-to-use report.
Product
Comprehensive molecular diagnostics
Fulgent Genetics, Inc. centers this product on broad molecular testing, with a portfolio spanning COVID-19, genetic, and oncology assays for healthcare and research users. Its lab-based model supports high-complexity testing across 18,000+ tests, helping it serve clinical demand beyond pandemic volume while keeping the business tied to recurring diagnostic workflows.
Oncology and solid tumor profiling
Fulgent Genetics, Inc. offers extensive oncology panels and solid-tumor molecular profiling to help identify cancer drivers and characterize tumors, including hematopoietic and solid tumors. Its molecular testing supports earlier, more precise treatment decisions, and its oncology menu spans hundreds of genes across DNA and RNA-based assays, giving clinicians a broader view of tumor biology.
Inherited disease screening
Beacon carrier screening anchors Fulgent Genetics, Inc.'s inherited disease panel, alongside newborn genetic analysis and ataxia-related variant testing. These tests are built for early detection and clinical decision support, which matters when about 1 in 33 U.S. babies is born with a birth defect.
Rapid whole genome testing
Fulgent Genetics, Inc. uses rapid whole genome testing to help NICU and PICU teams find genetic causes fast in critically ill infants. In published care pathways, rapid genome testing can deliver results in 24 to 72 hours and often shows about 20% to 40% diagnostic yield in high-acuity cases.
Its menu also includes whole exome, clinical exome, whole genome, mutation, and repeat expansion tests, so the product fits rare-disease workups and broader 4P positioning around precision, speed, and clinical utility. That mix supports higher-value, decision-critical testing.
- Fast results for ICU care
- Fits rare-disease diagnostics
- Broad test menu, one platform
COVID-19 and specialty lab services
Fulgent Genetics, Inc. uses COVID-19 and specialty lab services to widen its product mix beyond DNA testing, offering SARS-CoV-2 testing through NGS, RT-PCR, and antigen methods plus flow cytometry, FISH, IHC, and cytogenetics. That mix helps keep the lab relevant across infectious disease and oncology workflows. It also adds more test orders per client and supports recurring service revenue.
- NGS, RT-PCR, and antigen COVID-19 testing
- Flow cytometry and FISH services
- IHC and cytogenetics support oncology care
- Broadens revenue beyond genetics alone
Fulgent’s Broad Test Menu Delivers Fast, High-Yield Answers
Fulgent Genetics, Inc. positions Product around broad molecular testing, led by oncology, rare disease, and infectious disease assays across 18,000+ tests. Its rapid genome and exome services support NICU/PICU cases with 24–72 hour turnaround and about 20%–40% diagnostic yield in high-acuity settings. The mix is built for clinical decision use and recurring lab demand.
| Area | Key point |
|---|---|
| Menu size | 18,000+ tests |
| Rapid genome | 24–72 hours |
| Diagnostic yield | 20%–40% |
What is included in the product
Detailed Word Document
A concise, company-specific 4P analysis of Fulgent Genetics, Inc. that breaks down Product, Price, Place, and Promotion strategies with real-world context.
Editable Excel File
Distills Fulgent Genetics’ 4Ps into a quick, practical view that eases marketing confusion and speeds decision-making.
Reference Sources
Provides a concise, traceable bibliography of industry reports, regulatory filings, and peer benchmarks to speed due diligence and validate Fulgent Genetics assumptions.
Place
Temple City, California headquarters
Fulgent Genetics, Inc. is headquartered in Temple City, California, where it has operated since its 2011 founding. This U.S. base supports a wide customer set across clinical testing, pharma services, and research, with the company reporting $315.4 million in revenue for 2024. The Temple City hub anchors its Product, Place, and Promotion reach in one location.
Global healthcare delivery
Fulgent Genetics, Inc. serves healthcare providers and individuals globally, so its lab testing is not tied to one local market. That broad reach supports a wider geographic footprint for diagnostics and helps the company serve both U.S. and international demand. In its latest reported year, Company Name generated about $280 million in revenue, showing this global model is already material.
Provider and institutional channels
Fulgent Genetics reaches hospitals, medical institutions, fellow laboratories, payors, government agencies, municipal bodies, and large corporations through a B2B and institutional channel model. This setup fits its clinical testing and genomics focus, where buying decisions are driven by lab capacity, reimbursement, and contract relationships. In practice, that means fewer retail-style sales and more multi-site, high-trust accounts.
Direct-to-patient access
Picture Genetics gives Fulgent Genetics, Inc. a direct-to-patient path, letting consumers order genetic tests without a provider referral. That widens access beyond clinic-based sales and can pull in first-time buyers. It also fits the company’s consumer reach strategy in a market where testing can start online, then move to follow-up care.
- Direct consumer ordering
- Outside provider referrals
- Broader patient reach
Strategic commercialization partnership
Fulgent Genetics, Inc. partnered with Helio Health, Inc. to commercialize blood-based early cancer detection tests, adding a partner-led route to market. This helps widen reach without relying only on direct sales, and it can speed access to providers and patients. In 2025-2026, this kind of collaboration fits a low-capital, scale-first launch model.
- Partner-led access expands reach
- Supports faster test commercialization
Multi-Channel Reach Powers a $315M Revenue Footprint
Company Name’s Place mix is anchored by its Temple City, California HQ and lab network, but its reach is broader: it sells through U.S. healthcare systems, labs, payors, government buyers, and direct-to-patient channels, plus partner-led launches like Helio Health. 2024 revenue was $315.4 million, showing this multi-channel footprint is already material.
| Place channel | Role | Latest fact |
|---|---|---|
| Temple City HQ | Operating base | Founded 2011 |
| B2B healthcare | Core distribution | Multi-site accounts |
| Picture Genetics | DTC access | No referral needed |
| Partners | Market reach | Helio Health tie-up |
Full Version Awaits
Fulgent Genetics, Inc. Reference Sources
The preview shown here is the exact, full Fulgent Genetics, Inc. 4P's Marketing Mix analysis you'll receive immediately after purchase—no sample, no teaser.
This ready-made document is comprehensive, editable, and ready for use in strategy, valuation, or investor presentations right after checkout.
Promotion
Clinical utility positioning
Fulgent Genetics, Inc. promotes Promotion through clinical utility, not broad consumer appeal. Its test menu covers oncology, inherited conditions, and critical-care genetics, with more than 18,000 genes across its assay portfolio. That positioning speaks to providers who need fast diagnostic support, especially when test choice affects treatment.
Multi-segment customer outreach
Fulgent Genetics, Inc. sells to insurers, hospitals, labs, government agencies, and direct patients, so its promotion has to speak to each buyer’s job: coverage, turnaround time, test breadth, and clinical fit. That means the company uses one message for payers and a different one for clinicians and patients. In 2025, this multi-audience model matters because healthcare buying is still split across reimbursement, clinical use, and self-pay demand.
Picture Genetics branding
Picture Genetics lets Fulgent Genetics, Inc. push patient-initiated testing under a consumer brand, so awareness for direct genetic testing stays clear and distinct from provider-facing lab services. That split helps Fulgent Genetics, Inc. market to self-pay and curious consumers without blurring clinical messaging. It also supports a cleaner 4P promotion strategy by separating DTC outreach from B2B laboratory sales.
Partnership-based visibility
Helio Health gives Fulgent Genetics, Inc. a visible channel for early cancer detection work, which can lift trust and speed adoption. In diagnostics, partnerships often help a company move into more than one test category without building every route alone.
- Helio Health boosts credibility.
- It expands reach into new categories.
- It supports early cancer detection visibility.
Investor and corporate communications
Fulgent Genetics, Inc. uses investor and corporate communications to explain test launches and business updates through earnings materials, press releases, and SEC filings. In FY2025, that meant 4 quarterly updates plus 1 annual report, giving investors 5 formal disclosure touchpoints and steady visibility into revenue, margin, and test-volume trends.
- 5 FY2025 disclosure touchpoints
- Earnings, press, SEC filings
- Supports investor visibility
Fulgent’s Brand Split and Clinical Proof Deepen Trust
Fulgent Genetics, Inc. promotes through clinical proof, multi-audience messaging, and brand split. FY2025 investor outreach added 5 formal disclosure touchpoints, while Picture Genetics and Helio Health extended patient and early-cancer visibility. That mix supports payer trust, clinician adoption, and direct patient demand.
| FY2025 signal | Value |
|---|---|
| Disclosure touchpoints | 5 |
| Test menu size | 18,000+ genes |
Price
Reimbursement-driven pricing
Fulgent Genetics uses reimbursement-driven pricing: diagnostic test prices depend on insurer contracts, medical-necessity rules, and payer mix. Because Fulgent sells to insurance companies and payors, the list price is less important than what each payer agrees to reimburse, so patient out-of-pocket cost can swing with deductibles and coverage terms. This model can protect demand, but it also caps realized pricing and ties cash flow to claim approval speed.
Institutional contract pricing
Fulgent Genetics, Inc. uses negotiated institutional contract pricing for hospitals, laboratories, governments, and corporations, so rates vary by volume, test type, and service level. That fits a high-complexity lab model where bundled panels and rush work price differently than routine testing. In this setup, contract terms can drive repeat orders and protect margin on specialized assays.
Test-specific price variation
Fulgent Genetics, Inc. prices tests by complexity, so NGS, exome, genome, RT-PCR, antigen, and cytogenetic services do not sit at the same level. Deeper assays cost more because they use more reads, more lab work, and longer turnaround, while simpler tests are priced lower for speed and scale. That spread lets Fulgent match price to clinical scope, from quick detection to full genomic profiling.
Direct-patient cash pay options
Picture Genetics gives Fulgent Genetics, Inc. a direct-patient cash-pay path, so people can buy tests without insurer approval. That widens access for self-pay and out-of-network customers and can speed collection versus billing delays. Fulgent Genetics, Inc. can use this channel to reach demand that sits outside traditional reimbursement.
- Cash pay boosts access
- Works beside insurance billing
- Fits self-pay patients
- Reduces reimbursement friction
Value-based diagnostic pricing
Fulgent Genetics prices by clinical value, not by commodity volume. Its menu spans over 18,000 tests, so customers pay for specialized diagnostics, broader panels, and faster decision support rather than a single routine assay.
This supports premium pricing where medical utility is high, especially in oncology and rare disease testing. The model works because breadth and depth of service can justify higher reimbursement than basic lab work.
- Over 18,000 tests support tiered pricing
- Specialty assays back premium pricing
- Value comes from clinical utility
Fulgent’s Pricing Power Hinges on Payers, Test Mix, and Self-Pay
Fulgent Genetics prices on reimbursement and contract terms, so realized revenue depends on payer mix, medical necessity, and test complexity more than list price. In 2025, its menu still topped 18,000 tests, supporting tiered pricing from low-cost PCR to higher-priced NGS and whole-genome assays. Cash-pay Picture Genetics also gives it a direct self-pay route.
| Price driver | Implication |
|---|---|
| Payer contracts | Reimbursement sets realized price |
| Test complexity | NGS and genome tests price higher |
| Cash-pay channel | Reduces billing friction |
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.